# Page snapshot

```yaml
- generic [active] [ref=e1]:
  - navigation [ref=e2]:
    - generic [ref=e4]:
      - link "Skyvera" [ref=e6] [cursor=pointer]:
        - /url: /dashboard
        - img "Skyvera" [ref=e7]
      - generic [ref=e8]:
        - link "Dashboard" [ref=e9] [cursor=pointer]:
          - /url: /dashboard
          - img [ref=e10]
        - link "Accounts" [ref=e15] [cursor=pointer]:
          - /url: /accounts
          - img [ref=e16]
        - link "Alerts" [ref=e20] [cursor=pointer]:
          - /url: /alerts
          - img [ref=e21]
        - link "Scenarios" [ref=e24] [cursor=pointer]:
          - /url: /scenario
          - img [ref=e25]
        - link "DM Strategy" [ref=e29] [cursor=pointer]:
          - /url: /dm-strategy
          - img [ref=e30]
        - link "Ask" [ref=e33] [cursor=pointer]:
          - /url: /query
          - img [ref=e34]
  - main [ref=e36]:
    - generic [ref=e37]:
      - generic [ref=e38]:
        - heading "DM% Strategy & Revenue Retention" [level=1] [ref=e39]
        - paragraph [ref=e40]: AI-powered recommendations to optimize decline/maintenance rates, maximize recurring revenue, and strengthen customer retention across all business units.
        - generic [ref=e41]:
          - generic [ref=e42]:
            - generic [ref=e43]: 97.4%
            - generic [ref=e44]: This Month (Jan)
          - generic [ref=e45]:
            - generic [ref=e46]: 97.4%
            - generic [ref=e47]: This Quarter (Q1'26)
          - generic [ref=e48]:
            - generic [ref=e49]: Primary
            - generic [ref=e50]: 97.4%
            - generic [ref=e51]: TTM (12 Months)
          - generic [ref=e52]:
            - generic [ref=e53]: High Impact
            - generic [ref=e54]: $1.59M
            - generic [ref=e55]: Potential ARR Recovery
          - generic [ref=e56]:
            - generic [ref=e57]: "4"
            - generic [ref=e58]: Active Recommendations
          - generic [ref=e59]:
            - generic [ref=e60]: "140"
            - generic [ref=e61]: Accounts Analyzed
        - paragraph [ref=e63]: ğŸ’¡ Recommendations are prioritized by impact and confidence
      - link "ğŸ“Š View 12-Month DM% Trend Charts Visualize retention trends with interactive charts for each business unit â†’" [ref=e65] [cursor=pointer]:
        - /url: /dm-strategy/trends
        - generic [ref=e66]:
          - generic [ref=e67]:
            - heading "ğŸ“Š View 12-Month DM% Trend Charts" [level=3] [ref=e68]
            - paragraph [ref=e69]: Visualize retention trends with interactive charts for each business unit
          - generic [ref=e70]: â†’
      - generic [ref=e73]:
        - generic [ref=e74]:
          - heading "Business Units" [level=2] [ref=e75]
          - generic [ref=e76]:
            - generic [ref=e77] [cursor=pointer]:
              - generic [ref=e78]:
                - heading "Cloudsense" [level=3] [ref=e79]
                - generic [ref=e80]: "1"
              - generic [ref=e82]:
                - generic [ref=e83]:
                  - generic [ref=e84]: This Month (Jan)
                  - generic [ref=e85]: 94.7%
                - generic [ref=e86]:
                  - generic [ref=e87]: This Quarter (Q1)
                  - generic [ref=e88]: 94.7%
                - generic [ref=e89]:
                  - generic [ref=e90]: TTM (12 Mo.)
                  - generic [ref=e91]: 94.7%
                - generic [ref=e92]: "Target: 95.0%"
              - generic [ref=e93]:
                - generic [ref=e94]: â†“
                - generic [ref=e95]: "-2.3% vs Last Quarter"
              - generic [ref=e96]:
                - generic [ref=e97]:
                  - generic [ref=e98]: ARR
                  - generic [ref=e99]: $6.4M
                - generic [ref=e100]:
                  - generic [ref=e101]: Accounts
                  - generic [ref=e102]: "65"
                - generic [ref=e103]:
                  - generic [ref=e104]: Status
                  - generic [ref=e105]: âš ï¸ Below Target
            - generic [ref=e106] [cursor=pointer]:
              - generic [ref=e107]:
                - heading "Kandy" [level=3] [ref=e108]
                - generic [ref=e109]: "2"
              - generic [ref=e111]:
                - generic [ref=e112]:
                  - generic [ref=e113]: This Month (Jan)
                  - generic [ref=e114]: 97.8%
                - generic [ref=e115]:
                  - generic [ref=e116]: This Quarter (Q1)
                  - generic [ref=e117]: 97.8%
                - generic [ref=e118]:
                  - generic [ref=e119]: TTM (12 Mo.)
                  - generic [ref=e120]: 97.8%
                - generic [ref=e121]: "Target: 95.0%"
              - generic [ref=e122]:
                - generic [ref=e123]: â†‘
                - generic [ref=e124]: +0.8% vs Last Quarter
              - generic [ref=e125]:
                - generic [ref=e126]:
                  - generic [ref=e127]: ARR
                  - generic [ref=e128]: $3.3M
                - generic [ref=e129]:
                  - generic [ref=e130]: Accounts
                  - generic [ref=e131]: "45"
                - generic [ref=e132]:
                  - generic [ref=e133]: Status
                  - generic [ref=e134]: âœ“ On Target
            - generic [ref=e135] [cursor=pointer]:
              - generic [ref=e136]:
                - heading "STL" [level=3] [ref=e137]
                - generic [ref=e138]: "1"
              - generic [ref=e140]:
                - generic [ref=e141]:
                  - generic [ref=e142]: This Month (Jan)
                  - generic [ref=e143]: 122.2%
                - generic [ref=e144]:
                  - generic [ref=e145]: This Quarter (Q1)
                  - generic [ref=e146]: 122.2%
                - generic [ref=e147]:
                  - generic [ref=e148]: TTM (12 Mo.)
                  - generic [ref=e149]: 122.2%
                - generic [ref=e150]: "Target: 95.0%"
              - generic [ref=e151]:
                - generic [ref=e152]: â†‘
                - generic [ref=e153]: +25.2% vs Last Quarter
              - generic [ref=e154]:
                - generic [ref=e155]:
                  - generic [ref=e156]: ARR
                  - generic [ref=e157]: $804K
                - generic [ref=e158]:
                  - generic [ref=e159]: Accounts
                  - generic [ref=e160]: "30"
                - generic [ref=e161]:
                  - generic [ref=e162]: Status
                  - generic [ref=e163]: âœ“ On Target
        - generic [ref=e164]:
          - generic [ref=e165]:
            - button "All 4" [ref=e166] [cursor=pointer]:
              - text: All
              - generic [ref=e167]: "4"
            - button "Critical 0" [ref=e168] [cursor=pointer]:
              - text: Critical
              - generic [ref=e169]: "0"
            - button "High Impact 1" [ref=e170] [cursor=pointer]:
              - text: High Impact
              - generic [ref=e171]: "1"
            - button "Quick Wins 0" [ref=e172] [cursor=pointer]:
              - text: Quick Wins
              - generic [ref=e173]: "0"
          - generic [ref=e174]:
            - combobox [ref=e175] [cursor=pointer]:
              - option "All Categories" [selected]
              - option "Retention"
              - option "Expansion"
              - option "Pricing"
              - option "Product"
              - option "Engagement"
              - option "Health"
            - combobox [ref=e176] [cursor=pointer]:
              - option "All Priorities" [selected]
              - option "Critical"
              - option "High"
              - option "Medium"
              - option "Low"
          - generic [ref=e177]:
            - generic [ref=e178]:
              - generic [ref=e180]: ğŸŸ  High
              - generic [ref=e181]:
                - generic [ref=e182]: Portfolio-wide
                - generic [ref=e183]: Cloudsense
              - heading "Cloudsense Product Health Investigation" [level=3] [ref=e184]
              - paragraph [ref=e185]: Cloudsense shows declining DM% trend over recent quarters. Product satisfaction may be declining.
              - generic [ref=e186]:
                - generic [ref=e187]:
                  - generic [ref=e188]: DM% Impact
                  - generic [ref=e189]: +3.0%
                - generic [ref=e190]:
                  - generic [ref=e191]: ARR Impact
                  - generic [ref=e192]: $637.0K
                - generic [ref=e193]:
                  - generic [ref=e194]: Confidence
                  - generic [ref=e195]: 70%
              - generic [ref=e196]:
                - generic [ref=e197]: ğŸ“… 90 days
                - generic [ref=e198]: âš ï¸ High Risk
                - generic [ref=e199]: ğŸ·ï¸ Product
              - generic [ref=e200]:
                - button "âœ“ Accept & Create Action" [ref=e201] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e202] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e203] [cursor=pointer]
            - generic [ref=e204]:
              - generic [ref=e206]: ğŸŸ  High
              - generic [ref=e207]:
                - generic [ref=e208]: Portfolio-wide
                - generic [ref=e209]: Kandy
              - heading "Kandy Product Health Investigation" [level=3] [ref=e210]
              - paragraph [ref=e211]: Kandy shows declining DM% trend over recent quarters. Product satisfaction may be declining.
              - generic [ref=e212]:
                - generic [ref=e213]:
                  - generic [ref=e214]: DM% Impact
                  - generic [ref=e215]: +3.0%
                - generic [ref=e216]:
                  - generic [ref=e217]: ARR Impact
                  - generic [ref=e218]: $332.2K
                - generic [ref=e219]:
                  - generic [ref=e220]: Confidence
                  - generic [ref=e221]: 70%
              - generic [ref=e222]:
                - generic [ref=e223]: ğŸ“… 90 days
                - generic [ref=e224]: âš ï¸ High Risk
                - generic [ref=e225]: ğŸ·ï¸ Product
              - generic [ref=e226]:
                - button "âœ“ Accept & Create Action" [ref=e227] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e228] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e229] [cursor=pointer]
            - generic [ref=e230]:
              - generic [ref=e232]: ğŸŸ¢ Medium
              - generic [ref=e233]:
                - generic [ref=e234]: Portfolio-wide
                - generic [ref=e235]: Kandy
              - heading "Kandy Upsell & Expansion Opportunity" [level=3] [ref=e236]
              - paragraph [ref=e237]: Kandy DM% is strong at 97.8%. Healthy retention creates ideal conditions for expansion.
              - generic [ref=e238]:
                - generic [ref=e239]:
                  - generic [ref=e240]: DM% Impact
                  - generic [ref=e241]: +2.0%
                - generic [ref=e242]:
                  - generic [ref=e243]: ARR Impact
                  - generic [ref=e244]: $498.4K
                - generic [ref=e245]:
                  - generic [ref=e246]: Confidence
                  - generic [ref=e247]: 70%
              - generic [ref=e248]:
                - generic [ref=e249]: ğŸ“… Q2'26
                - generic [ref=e250]: âš ï¸ Medium Risk
                - generic [ref=e251]: ğŸ·ï¸ Expansion
              - generic [ref=e252]:
                - button "âœ“ Accept & Create Action" [ref=e253] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e254] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e255] [cursor=pointer]
            - generic [ref=e256]:
              - generic [ref=e258]: ğŸŸ¢ Medium
              - generic [ref=e259]:
                - generic [ref=e260]: Portfolio-wide
                - generic [ref=e261]: STL
              - heading "STL Upsell & Expansion Opportunity" [level=3] [ref=e262]
              - paragraph [ref=e263]: STL DM% is strong at 122.2%. Healthy retention creates ideal conditions for expansion.
              - generic [ref=e264]:
                - generic [ref=e265]:
                  - generic [ref=e266]: DM% Impact
                  - generic [ref=e267]: +2.0%
                - generic [ref=e268]:
                  - generic [ref=e269]: ARR Impact
                  - generic [ref=e270]: $120.6K
                - generic [ref=e271]:
                  - generic [ref=e272]: Confidence
                  - generic [ref=e273]: 70%
              - generic [ref=e274]:
                - generic [ref=e275]: ğŸ“… Q2'26
                - generic [ref=e276]: âš ï¸ Medium Risk
                - generic [ref=e277]: ğŸ·ï¸ Expansion
              - generic [ref=e278]:
                - button "âœ“ Accept & Create Action" [ref=e279] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e280] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e281] [cursor=pointer]
        - generic [ref=e284]:
          - generic [ref=e285]:
            - heading "ğŸ“Š Projected Impact" [level=3] [ref=e286]
            - paragraph [ref=e287]: Based on 0 of 4 recommendations
          - generic [ref=e288]:
            - generic [ref=e289]: DM% Rate
            - generic [ref=e290]:
              - generic [ref=e291]:
                - generic [ref=e292]: Current
                - generic [ref=e293]: 104.9%
              - generic [ref=e294]: â†’
              - generic [ref=e295]:
                - generic [ref=e296]: Projected
                - generic [ref=e297]: 104.9%
          - generic [ref=e298]:
            - generic [ref=e299]: +0.0%
            - generic [ref=e300]: DM% Improvement
          - generic [ref=e301]:
            - generic [ref=e302]: Annual Recurring Revenue
            - generic [ref=e303]:
              - generic [ref=e304]:
                - generic [ref=e305]: Current
                - generic [ref=e306]: $10.50M
              - generic [ref=e307]: â†’
              - generic [ref=e308]:
                - generic [ref=e309]: Projected
                - generic [ref=e310]: $10.50M
          - generic [ref=e311]:
            - generic [ref=e312]: $0
            - generic [ref=e313]: Additional ARR
          - generic [ref=e315]:
            - generic [ref=e316]: Implementation Progress
            - generic [ref=e317]: 0/4
          - button "âš¡ Accept All High Priority" [ref=e319] [cursor=pointer]
          - generic [ref=e320]:
            - generic [ref=e321]: Key Metrics
            - generic [ref=e322]:
              - generic [ref=e323]: DM% Lift
              - generic [ref=e324]: 0.0 pts
            - generic [ref=e325]:
              - generic [ref=e326]: ARR Growth
              - generic [ref=e327]: 0.0%
            - generic [ref=e328]:
              - generic [ref=e329]: Confidence
              - generic [ref=e330]: High
      - paragraph [ref=e333]:
        - text: âœ“
        - strong [ref=e334]: "Live Data:"
        - text: Connected to DM tracker data (3 business units, 4 recommendations)
  - region "Notifications alt+T"
  - button "Open Next.js Dev Tools" [ref=e340] [cursor=pointer]:
    - img [ref=e341]
  - alert [ref=e344]
```